Poseida Therapeutics, Inc.2024财年第二财季实现净利润-31.37百万美元，同比减少14.24%

自选股智能写手08-17

8月17日，Poseida Therapeutics, Inc.（PSTX.US）公布财报，公告显示公司2024财年第二财季净利润为-31.37百万美元，同比减少14.24%；其中营业收入为25.97百万美元，同比增加29.79%，每股基本收益为-0.32美元。从资产负债表来看，Poseida Therapeutics, Inc.（PSTX.US）总负债2.38亿美元，其中短期债务6.04百万美元...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460902249?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-17 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460902249","market":"us","top_or_hot":-1,"title":"Poseida Therapeutics, Inc.2024财年第二财季实现净利润-31.37百万美元，同比减少14.24%","media":"自选股智能写手","content":"<div>\n<p>8月17日，Poseida Therapeutics, Inc.（PSTX.US）公布财报，公告显示公司2024财年第二财季净利润为-31.37百万美元，同比减少14.24%；其中营业收入为25.97百万美元，同比增加29.79%，每股基本收益为-0.32美元。从资产负债表来看，Poseida Therapeutics, Inc.（PSTX.US）总负债2.38亿美元，其中短期债务6.04百万美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005269f31b088&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Poseida Therapeutics, Inc.2024财年第二财季实现净利润-31.37百万美元，同比减少14.24%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPoseida Therapeutics, Inc.2024财年第二财季实现净利润-31.37百万美元，同比减少14.24%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-17 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005269f31b088&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月17日，Poseida Therapeutics, Inc.（PSTX.US）公布财报，公告显示公司2024财年第二财季净利润为-31.37百万美元，同比减少14.24%；其中营业收入为25.97百万美元，同比增加29.79%，每股基本收益为-0.32美元。从资产负债表来看，Poseida Therapeutics, Inc.（PSTX.US）总负债2.38亿美元，其中短期债务6.04百万美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005269f31b088&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSTX","symbol_name":"Poseida Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005269f31b088&s=b","article_id":"2460902249","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408170005269f31b088&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460902249","pubTimestamp":1723824033,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月17日，Poseida Therapeutics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-31.37百万美元，同比减少14.24%；其中营业收入为25.97百万美元，同比增加29.79%，每股基本收益为-0.32美元。从资产负债表来看，Poseida Therapeutics, Inc.总负债2.38亿美元，其中短期债务6.04百万美元，资产负债比为1.26，流动比率为2.50。机构评级：截至2024年8月17日，当前有3家机构对Poseida Therapeutics, Inc.目标价做出预测，其中目标均价为14.00美元，其中最低目标价为10.00美元，最高目标价为20.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"PSTX":"Poseida Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Poseida Therapeutics, Inc. achieved net profit of-US $31.37 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 14.24%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"PSTX":1},"content_text":"8月17日，Poseida Therapeutics, Inc.（PSTX.US）公布财报，公告显示公司2024财年第二财季净利润为-31.37百万美元，同比减少14.24%；其中营业收入为25.97百万美元，同比增加29.79%，每股基本收益为-0.32美元。从资产负债表来看，Poseida Therapeutics, Inc.（PSTX.US）总负债2.38亿美元，其中短期债务6.04百万美元，资产负债比为1.26，流动比率为2.50。机构评级：截至2024年8月17日，当前有3家机构对Poseida Therapeutics, Inc.目标价做出预测，其中目标均价为14.00美元，其中最低目标价为10.00美元，最高目标价为20.00美元。公司简介：Poseida Therapeutics Inc是一家临床阶段的生物制药公司，致力于利用非病毒基因工程技术为患有高度未满足医疗需求的患者创造拯救生命的疗法。 它已建立了自体和同种异体嵌合抗原受体T细胞或CAR-T候选产品线，最初专注于治疗血液恶性肿瘤和实体瘤。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460902249"}